Development of the first brain penetrant BRD4 inhibitors for cancer

TITLE:  Development of the first brain penetrant BRD4 inhibitors for cancer

ABSTRACT.  Our research at X-Chem Montreal (formerly Intellisyn Pharma) focusses on the discovery and development of novel drugs for central nervous system (CNS) disorders, cancer, infection, and metabolic disorders. In this seminar, we will first describe the development of CNS-penetrant BRD4 inhibitors for cancer from initial concept to Phase-1.

 Bio: 

Jeffrey Albert.  Jeff did his PhD at the University of Pittsburgh and post-doc at Caltech.  He then joined AstraZeneca where he spent 15 years at their sites in the US and in Montreal.  Over 15 years his work focused on lead generation, fragment-based drug discovery and CNS therapeutics.  In 2012 he founded “IntelliSyn Pharma” in Montreal to continue research in CNS therapeutics, and in 2016 founded “Avisyn Pharma” in San Diego.  In the last 10 years, IntelliSyn has over 40 patent applications and developed 9 drugs that are now in Phase-1 and beyond.  In 2021 IntelliSyn was acquired by X-Chem in Boston, and Jeff continues in Montreal and serves as Executive VP and Director of Medicinal Chemistry.

Meet with us!  If you would like to schedule an on-site interview or just an informal introductory meeting, click here.

Jeffrey Albert

X Chem, Inc.

e: jalbert@x-chemrx.com
| w: www.x-chemrx.com

a: 7171 Frederick Banting , Montreal , QC Canada
H4S 1Z9